Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway

DOI HANDLE Web Site 3 Citations 146 References Open Access
  • Itatani, Yoshiro
    Department of Surgery, Graduate School of Medicine, Kyoto University
  • Kawada, Kenji
    Department of Surgery, Graduate School of Medicine, Kyoto University
  • Yamamoto, Takamasa
    Department of Surgery, Graduate School of Medicine, Kyoto University・Moores Cancer Center, University of California San Diego
  • Sakai, Yoshiharu
    Department of Surgery, Graduate School of Medicine, Kyoto University

Bibliographic Information

Other Title
  • Resistance to anti-angiogenic therapy in cancer-alterations to anti-VEGF pathway.

Abstract

Anti-angiogenic therapy is one of the promising strategies for many types of solid cancers. Bevacizumab (Avastin), a recombinant humanized monoclonal antibody of vascular endothelial growth factor (VEGF) A, was approved for the first time as an anti-angiogenic drug for the treatment of metastatic colorectal cancer (CRC) by the Food and Drug Administration (FDA) in 2004. In addition, the other VEGF pathway inhibitors including small molecule tyrosine kinase inhibitors (sunitinib, sorafenib, and pazopanib), a soluble VEGF decoy receptor (aflibercept), and a humanized monoclonal antibody of VEGF receptor 2 (VEGFR2) (ramucirumab) have been approved for cancer therapy. Although many types of VEGF pathway inhibitors can improve survival in most cancer patients, some patients have little or no beneficial effect from them. The primary or acquired resistance towards many oncological drugs, including anti-VEGF inhibitors, is a common problem in cancer treatment. This review summarizes the proposed alternative mechanisms of angiogenesis other than the VEGF pathway. These mechanisms are involved in the development of resistance to anti-VEGF therapies in cancer patients.

Journal

Citations (3)*help

See more

References(146)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top